Molly Henderson Phathom Pharmaceuticals, Inc. (PHAT) insider trading activity

Molly Henderson is CFO and CBO of Phathom Pharmaceuticals, Inc.. Currently has a direct ownership of 89,868 shares of PHAT, which is worth approximately $593,128. The most recent transaction as insider was on Apr 07, 2025, when has been sold 3,678 shares (Common Stock) at a price of $4.55 per share, resulting in proceeds of $16,734. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 89.9K

8.44% 3M change

5.66% 12M change

Total Value Held $593,128

Molly Henderson Transaction History

Date	Transaction	Value	Shares Traded	Shares Held
Apr 07 2025	SELL Open market or private sale	$16,734 $4.55 p/Share	3,678 Reduced 3.93%	89,868 Common Stock
Feb 27 2025	BUY Grant, award, or other acquisition	-	72,000 Added 30.31%	165,546 Common Stock
Jan 21 2025	SELL Open market or private sale	$43,381 $6.59 p/Share	6,583 Reduced 6.57%	93,546 Common Stock
Dec 19 2024	SELL Open market or private sale	$10,328 $8.0 p/Share	1,291 Reduced 1.3%	98,156 Common Stock
Jul 15 2024	SELL Open market or private sale	$50,689 $11.72 p/Share	4,325 Reduced 4.17%	99,447 Common Stock
May 31 2024	BUY Grant, award, or other acquisition	-	7,500 Added 6.8%	102,763 Common Stoock
Apr 08 2024	SELL Open market or private sale	$38,128 $11.1 p/Share	3,435 Reduced 3.48%	95,263 Common Stoock
Jan 19 2024	SELL Open market or private sale	$48,879 $7.75 p/Share	6,307 Reduced 6.01%	98,698 Common Stock
Nov 20 2023	SELL Open market or private sale	$15,399 $7.24 p/Share	2,127 Reduced 2.02%	103,061 Common Stock
Nov 01 2023	SELL Open market or private sale	$104,682 $8.38 p/Share	12,492 Reduced 10.62%	105,188 Common Stock
Nov 01 2023	BUY Grant, award, or other acquisition	-	22,500 Added 16.05%	117,680 Common Stock
Jul 14 2023	BUY Grant, award, or other acquisition	$25,000 $1.0 p/Share	25,000 Added 20.8%	95,180 Common Stock
Jun 02 2023	SELL Open market or private sale	$22,363 $11.41 p/Share	1,960 Reduced 2.78%	68,506 Common Stock
May 22 2023	SELL Open market or private sale	$27,155 $12.87 p/Share	2,110 Reduced 2.91%	70,466 Common Stock
Apr 06 2023	SELL Open market or private sale	$25,001 $7.27 p/Share	3,439 Reduced 4.52%	72,576 Common Stock
Mar 01 2023	SELL Open market or private sale	$17,332 $8.53 p/Share	2,032 Reduced 2.6%	76,015 Common Stock
Jan 19 2023	BUY Grant, award, or other acquisition	-	33,000 Added 29.72%	78,047 Common Stock
Nov 21 2022	SELL Open market or private sale	$20,726 $9.6 p/Share	2,159 Reduced 4.75%	43,341 Common Stock
Sep 01 2022	BUY Grant, award, or other acquisition	-	7,500 Added 14.15%	45,500 Common Stock
May 19 2022	BUY Grant, award, or other acquisition	-	12,000 Added 24.0%	38,000 Common Stock
May 13 2022	BUY Open market or private purchase	-	6,000 Added 18.75%	26,000 Common Stock
Apr 05 2022	BUY Grant, award, or other acquisition	-	20,000 Added 50.0%	20,000 Common Stock

Also insider at

URGN

UroGen Pharma Ltd. Healthcare

Chief Financial Officer

Molly Henderson

CFO and CBO

Florham, NJ

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells PHAT shares.

Notify only if

Value

Insider Trading

Get notified when an Phathom Pharmaceuticals, Inc. insider buys or sells PHAT shares.

Notify only if

Operation

Value

Type

News

Receive news related to Phathom Pharmaceuticals, Inc.

Track Activities on PHAT

Account